查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941692

細胞療法市場規模、佔有率、趨勢及預測（按細胞類型、治療方法、治療領域、最終用戶和地區分類），2026-2034年

Cell Therapy Market Size, Share, Trends and Forecast by Cell Type, Therapy Type, Therapeutic Area, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2025年全球細胞治療市場規模為180億美元。 IMARC Group預測，到2034年，該市場規模將達到610億美元，2026年至2034年的複合年成長率（CAGR）為14.55%。北美目前佔據市場主導地位，預計2025年將佔據超過59.8%的市場。隨著全球醫療基礎設施的完善，幹細胞研究的進展也正在加速。意識提升、政府支持的加強以及保險覆蓋範圍的擴大也是推動市場發展的關鍵因素。

細胞療法市場的發展主要得益於再生醫學的進步、研發投入的增加以及癌症和自體免疫疾病等慢性病的盛行率上升。幹細胞技術和CAR-T療法的創新正在提高治療效果，並促進其廣泛應用。例如，2024年6月，南加州大學的研究人員開發了一種利用機器學習的非侵入性成像方法，用於研究造血幹細胞。這項突破性技術能夠即時追蹤幹細胞的行為和代謝，加深我們對幹細胞複製和分化的理解。這可能對骨髓移植和再生醫學等治療方法產生深遠影響。監管部門的核准和不斷增加的臨床試驗進一步推動了市場成長。對個人化醫療日益成長的需求推動了人們對細胞療法的興趣，而不斷完善的醫療基礎設施和報銷政策則提高了其可及性。此外，生技公司和研究機構之間的合作正在加速突破，使細胞療法成為滿足全球醫療保健未滿足需求的理想解決方案。

美國細胞療法市場的發展動力源於對慢性疾病（尤其是癌症和自體免疫疾病）創新治療方法日益成長的需求。根據美國國家癌症研究所發布的數據，預計到2024年，美國將新增約2,001,140例癌症病例，並有611,720人死於癌症。其中，乳癌、攝護腺癌、肺癌和大腸癌是主要癌症類型，分別佔男性癌症診斷總數的48%和女性癌症診斷總數的51%。癌症發生率的上升正在推動美國各地對細胞療法的需求。 CAR-T細胞療法和幹細胞研究的進展是市場擴張的關鍵促進因素。政府的大力資助、不斷增加的臨床試驗以及快速的監管核准正在強化開發平臺。個人化醫療的普及，以及醫療基礎設施和報銷機制的完善，正在加速細胞療法的應用。此外，生物技術公司、學術機構和製藥公司之間的合作也在促進創新。

細胞療法市場趨勢：

包括癌症和心臟病在內的各種疾病的發生率增加

包括癌症和心臟病在內的多種疾病日益普遍，對市場產生了積極影響。由於人口老化、生活方式改變和環境因素等原因，這些疾病的全球負擔正在穩步加重。世界衛生組織（WHO）的數據顯示，2020年全球新增癌症病例約1,930萬例，凸顯了創新治療方法的迫切需求。細胞療法利用特化細胞的再生和修復能力，具有治療甚至治癒多種疾病的潛力。在癌症治療方面，CAR-T細胞療法等以細胞為基礎的免疫療法在標靶和清除癌細胞方面取得了顯著成效。在心臟病治療方面，基於幹細胞的治療方法旨在修復受損的心臟組織並改善心臟功能。對這些廣泛流行且危及生命的疾病進行有效治療方法的迫切需求，正在推動細胞療法領域的廣泛研究、開發和投資。

增加對細胞療法的臨床研究

細胞療法臨床研究數量的不斷成長正在推動細胞療法市場的發展。根據ClinicalTrials.gov網站統計，截至2024年，全球已有超過2,000項臨床試驗正在進行中。臨床試驗在檢驗這些創新治療方法的安全性和有效性方面發揮著至關重要的作用。隨著臨床研究的拓展，包括癌症、自體免疫疾病和退化性疾病在內的多種疾病對創新治療方法的需求日益成長。生技公司、製藥公司和學術機構正積極進行這些研究，旨在實現細胞療法的商業化。這些研究獲得的大量數據不僅展現了細胞療法的治療潛力，還有助於改進治療通訊協定並確定最佳患者群體。此外，美國食品藥物管理局（FDA）等監管機構也積極支持並加速細胞療法的核准流程，進一步促進了臨床試驗的啟動。因此，越來越多的臨床試驗正在推動細胞療法的發展，激發創新思維，同時擴大有需要的患者獲得治療的機會。這項因素凸顯了臨床研究在推動市場發展的重要角色。

全球不斷擴張的醫療保健產業

全球醫療保健產業的蓬勃發展為市場帶來了光明的前景。隨著人口成長和老化，慢性疾病負擔日益加重，對先進療法的需求也顯著成長。醫療保健產業的擴張也包括細胞療法等最先進治療的研發。全球醫療保健系統日益認知到細胞療法在治療包括自體免疫、神經系統疾病、心血管疾病和癌症在內的多種疾病方面的潛力。這種日益成長的認知促使再生醫學和細胞療法領域的投資、研究和臨床試驗不斷增加。此外，新興國家醫療基礎設施的建設也擴大了包括細胞療法在內的前沿療法的可近性。目前，全球有超過1200項臨床試驗正在評估細胞療法，凸顯了研究工作的持續深入。全球醫療保健服務的擴張擴大了細胞療法的潛在患者群體，從而推動了市場成長。

目錄

第1章：序言

第2章：調查範圍與調查方法

  • 調查目標
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章 引言

第5章 全球細胞治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 依細胞類型分類的市場細分

  • 幹細胞
    • 主要部分
      • 骨髓
      • 血
      • 臍帶來源
      • 脂肪來源幹細胞
      • 其他
  • 非幹細胞

第7章 按治療方法分類的市場區隔

  • 自體移植
  • 同種異體移植

第8章 按治療領域分類的市場區隔

  • 惡性腫瘤
  • 肌肉骨骼疾病
  • 自體免疫疾病
  • 皮膚科
  • 其他

第9章 依最終用戶分類的市場細分

  • 醫院和診所
  • 學術研究機構

第10章 按地區分類的市場細分

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章 價值鏈分析

第13章 波特五力分析

第14章：定價分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Allogene Therapeutics
    • AlloSource
    • Bristol-Myers Squibb Company
    • Corestemchemon Inc
    • Gilead Sciences, Inc.
    • Holostem Srl
    • IOVANCE Biotherapeutics, Inc.
    • JCR Pharmaceuticals Co., Ltd
    • Legend Biotech
    • Mesoblast Ltd.
    • Sangamo Therapeutics
    • Tegoscience
    • Vericel Corporation
Product Code: SR112026A6231

The global cell therapy market size was valued at USD 18.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 61.0 Billion by 2034, exhibiting a CAGR of 14.55% during 2026-2034. North America currently dominates the market, holding a significant market share of over 59.8% in 2025. The advancements in stem cell research are on the rise along with the development of healthcare infrastructure worldwide. Increasing patient awareness, heightened government support and broader insurance coverage are also key factors driving the market forward.

The cell therapy market is driven by advancements in regenerative medicine, increasing investment in research and development and rising prevalence of chronic diseases like cancer and autoimmune disorders. Innovations in stem cell technology and CAR-T therapies are enhancing treatment effectiveness, and driving adoption. For instance, in June 2024, researchers at USC developed a non-invasive imaging method using machine learning to study hematopoietic stem cells. This breakthrough allows for real-time tracking of stem cell behavior and metabolism improving understanding of their replication and differentiation with potential implications for therapies like bone marrow transplants and regenerative medicine. Regulatory approvals and growing clinical trials further boost market growth. The demand for personalized medicine is fostering interest in cell based therapies while expanding healthcare infrastructure and reimbursement policies to support accessibility. Additionally, collaborations between biotech companies and research institutions are accelerating breakthroughs making cell therapies a promising solution for unmet medical needs in global healthcare.

The United States cell therapy market is fueled by growing demand for innovative treatments for chronic diseases, particularly cancer and autoimmune disorders. According to data published by the National Cancer Institute, in 2024 the United States will witness approximately 2,001,140 new cancer cases with 611,720 deaths. Common cancers include breast, prostate, lung and colorectal comprising 48% of diagnoses in men and 51% in women. Rising incidence of cancer is driving the demand for cell therapy across the country. Advancements in CAR-T cell therapy and stem cell research are key contributors to market expansion. Robust government funding, increasing clinical trials and faster regulatory approvals enhance the development pipeline. The adoption of personalized medicine is accelerating the use of cell therapies supported by improved healthcare infrastructure and reimbursement frameworks. Additionally, collaborations between biotech firms, academic institutions and pharmaceutical companies are fostering innovation.

Cell Therapy Market Trends:

Increasing Prevalence of Various Diseases, Such as Cancer and Cardiac Abnormalities

The increasing prevalence of various diseases particularly cancer and cardiac abnormalities is favorably impacting the market. The global burden of these diseases has steadily risen due to factors like aging populations, lifestyle changes and environmental influences. According to the World Health Organization (WHO), cancer accounted for approximately 19.3 million new cases globally in 2020, highlighting the urgent need for innovative therapies. By using the regenerative and reparative capabilities of specialized cells, cell therapy has enormous potential for treating and even curing various diseases. For cancer, cell-based immunotherapies such as CAR-T cell therapy have shown remarkable success in targeting and eliminating cancer cells. In the case of cardiac abnormalities stem cell-based therapies aim to repair damaged heart tissue and improve cardiac function. The urgent need for effective treatments for these widespread and life-threatening diseases propels extensive research, development, and investment in cell therapy approaches.

Rising Number of Clinical Studies for Cell-based Therapies

The rising number of clinical studies for cell based therapies is fueling the cell therapy market growth with over 2,000 active clinical trials globally as of 2024, according to ClinicalTrials.gov. Clinical trials play a fundamental role in validating the safety and efficacy of these innovative treatments. The need for innovative treatments to treat a range of illnesses, including cancer, autoimmune diseases, and degenerative disorders, is increasing as clinical research expands. These studies are being actively carried out by biotechnology firms, pharmaceutical corporations, and academic institutions to commercialize cell-based medicines. The wealth of data generated from these studies demonstrates the therapeutic potential of cell therapies but also aids in refining treatment protocols and identifying the most suitable patient populations. Moreover, regulatory agencies like the FDA in the United States actively support and expedite the approval process for cell-based therapies further incentivizing the initiation of clinical trials. Consequently, a rising number of clinical trials propels the development of cell therapies, encouraging creativity and boosting their availability to patients in need. This factor underscores the significant role clinical research plays in propelling the market.

Expanding Healthcare Industry Worldwide

The growing healthcare sector across the globe is creating a positive market outlook. As populations grow, age and face an increasing burden of chronic diseases the demand for advanced medical treatments rises significantly. The healthcare sector's expansion includes the development of cutting-edge therapies like cell-based treatments. Global healthcare systems are realizing that cell therapy can be used to treat a variety of illnesses, including autoimmune diseases, neurological disorders, cardiovascular diseases, and cancer. This recognition translates into increased investment, research and clinical trials in regenerative medicine and cell therapy. Furthermore, access to cutting-edge medical treatments, such as cell therapies, is increasing in emerging nations as healthcare infrastructure advances. Additionally, over 1,200 clinical trials globally are currently evaluating cell therapies highlighting growing research efforts. This global expansion of healthcare services broadens the potential patient pool for cell-based treatments driving market growth.

Cell Therapy Industry Segmentation:

Analysis by Cell Type:

  • Stem Cell
    • Bone Marrow
    • Blood
    • Umbilical Cord-Derived
    • Adipose-Derived Stem Cell
    • Others
  • Non-stem Cell

Stem cells with their remarkable regenerative potential and ability to differentiate into various cell types have garnered significant attention in the medical field. These versatile cells are instrumental in treating a wide spectrum of diseases including degenerative disorders, neurological conditions and hematological malignancies. The increasing prevalence of age-related diseases and chronic conditions has intensified the demand for effective stem cell-based treatments. Moreover, ongoing research and clinical trials continue to unveil new therapeutic possibilities for stem cells further fueling market growth. Pharmaceutical and biotechnology firms heavily invest in stem cell research focusing on developing innovative therapies. Furthermore, regulatory agencies are recognizing the importance of stem cell therapies, streamlining approval processes and safety standards. This facilitates the commercialization of stem cell-based treatments making them more accessible to patients worldwide. The stem cell segment is a powerful driver of growth in the cell therapy market promising revolutionary solutions for numerous medical challenges.

Analysis by Therapy Type:

  • Autologous
  • Allogeneic

Autologous leads the market with around 91.6% of market share in 2025. Autologous therapies involve the extraction, manipulation and reinfusion of a patient's cells minimizing the risk of rejection and adverse reactions. This personalized approach has gained prominence in treating various conditions including cancer, autoimmune diseases and degenerative disorders. The increasing demand for therapies with higher safety profiles and reduced immune complications has fueled the adoption of autologous cell therapies. These treatments harness the regenerative potential of a patient's cells addressing unmet medical needs while minimizing the risks associated with allogeneic treatments where cells are sourced from donors.

Furthermore, advancements in cell processing techniques such as CAR-T cell therapies for cancer treatment showcase the remarkable potential of autologous therapies. Regulatory agencies are also streamlining approval pathways for these personalized treatments expediting their availability to a wider patient population. As a result the autologous therapy segment is a pivotal driver of growth in the cell therapy market offering innovative and patient-centric solutions for various medical conditions.

Analysis by Therapeutic Area:

  • Malignancies
  • Musculoskeletal Disorders
  • Autoimmune Disorders
  • Dermatology
  • Others

Malignancies including various types of cancer present one of the most challenging healthcare concerns globally. Cell therapies such as CAR-T have emerged as groundbreaking treatments for these conditions. The growing incidence of cancer and the increasing demand for more effective and targeted therapies have propelled the development and adoption of cell based treatments. These therapies harness the patient's immune system or engineered cells to target and eliminate cancer cells. Their remarkable success in clinical trials and real-world applications underscores their potential to transform cancer treatment.

Moreover, regulatory agencies are expediting approvals for cell therapies in oncology streamlining their path to market. As a result, the malignancies focused segment serves as a critical driver of growth in the cell therapy market offering renewed hope to cancer patients and contributing to the evolution of cancer care. The cell therapy market forecast anticipates sustained growth driven by the demand for innovative and targeted treatments like CAR-T therapy particularly within the oncology segment.

Analysis by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Hospitals and clinics serve as primary end users of cell therapy due to their advanced infrastructure and skilled medical staff. These facilities support a range of therapies including regenerative treatments for chronic diseases, cancer and autoimmune disorders. The growing prevalence of conditions requiring cell-based solutions combined with increasing patient awareness drives the adoption of cell therapy in these settings. Moreover, advancements in stem cell banking and enhanced government funding for hospital based research further strengthen their role in the cell therapy market.

Academic and research institutes are key end users in the cell therapy market driving innovation and development. These centers study cellular mechanisms, test new therapies, and conduct clinical trials. Their access to specialized labs and collaborative networks enables the development of cutting-edge treatments. Government and private funding initiatives for R&D alongside partnerships with biotech firms amplify their contributions to the market. These institutions are vital for translating scientific breakthroughs into clinical applications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 59.8%. North America boasts a robust and highly developed healthcare infrastructure including advanced research institutions, hospitals and clinical centers. These institutions actively engage in cell therapy research and clinical trials accelerating the development and adoption of innovative cell-based treatments. The substantial investments in the biotechnology and pharmaceutical sectors facilitate the advancement of cell therapies. Pharmaceutical companies and biotech firms in the region actively contribute to cell therapy research and development resulting in a steady stream of new therapies.

The regulatory agencies in North America such as the FDA in the United States play a crucial role in streamlining the approval process for cell therapies ensuring they meet rigorous safety and efficacy standards. This regulatory support expedites the commercialization of these treatments. Moreover, the increasing prevalence of chronic diseases including cancer fuels the demand for effective and advanced therapies making cell therapies an attractive option for patients and healthcare providers.

Key Regional Takeaways:

United States Cell Therapy Market Analysis

In 2025, the United States accounted for a share of 92.80% of the North America market. With immense investment in R&D and clinical advancements, the U.S. cell therapy market is booming. According to the Alliance for Regenerative Medicine, global cell and gene therapy investment has hit USD 23.1 Billion in 2023; most of which have come from the United States. The high prevalence of chronic diseases such as cancer and diabetes fuels the adoption of therapies like CAR-T and stem cell treatment, together with favorable FDA policies. Focus is put on innovation, as from 2023 when over 2,000 clinical trials for cell therapy had already been running. Leading players in this space include companies from Novartis and Gilead Sciences, with new pipeline growth from collaboration with academia and biotech companies. In developing initiatives, the government-initiated schemes, such as the 21st Century Cures Act, are complemented by collaboration with payers over the cost issues. The US is also using export opportunities to build on its leadership position worldwide in cell therapy.

Europe Cell Therapy Market Analysis

Europe has a growing cell therapy market, thanks to strong R&D support, advances in regulations, and increasing healthcare budgets. In 2023, more than 150 ATMPs, including cell therapies, were in some form of clinical trials according to EMA. Germany is on top with considerable funding that was allocated to regenerative medicine projects last 2022 to the tune of USD 200 Million. The growth in the region is driven by CAR-T cell therapies for oncology and mesenchymal stem cells for degenerative diseases. The Association of the British Pharmaceutical Industry stated that there are over 90 cell therapy companies in the UK, which contribute highly to exports and employment. The EU regulations focus on safety and innovation, which encourages the use of innovative technologies. The collaboration between universities and biotech firms is enhancing the competitiveness of the market in the global arena. Such is the case for France and the Netherlands.

Asia Pacific Cell Therapy Market Analysis

The Asia Pacific cell therapy market is growing rapidly owing to the increasing investments and regional advancements in health care. India's Biotechnology Industry Research Assistance Council released USD 500 Million in 2023 for translational research. Japan's Act on the Safety of Regenerative Medicine and streamlined regulatory routes have accelerated market growth, with more than 30 cell therapies approved by 2023. Several countries, such as South Korea and Australia, are leading early clinical trials for new therapies via state-sponsored work. The partnerships between regional biotech companies and global leaders, like the CAR-T collaboration by Fosun Kite Biotechnology, are drivers of technology transfer. Also, low manufacturing cost in the region will give the Asia Pacific a critical place in the global cell therapy landscape.

Latin America Cell Therapy Market Analysis

Government support and increased local manufacturing drive Latin America's momentum in cell therapy. According to ProMedica International, biopharmaceuticals are allocated to the tune of USD 1.5 Billion, as announced in 2022 by Brazil. Clinical trials in Mexico will be focused on the increasing number of infrastructures; 50 or more trials were ongoing at the end of 2023. Other conditions that require regenerative medicine are type 2 diabetes and cardiovascular diseases. Colombia is also investing in stem cell research. Academic collaborations and government funding support the effort. A leader in the industry is Cellavita in Brazil, which is increasing production capacity to meet both the local and export markets. In addition, innovations in manufacturing cost-effective cell therapy help improve healthcare access in this region. Partnerships with global biotechnology companies will further strengthen Latin America's position in the global market while promoting regional R&D capabilities.

Middle East and Africa Cell Therapy Market Analysis

Middle East and Africa the cell therapy market is steadily growing on account of healthcare modernization and research investment. For instance, in 2023, the International Trade Administration reported that Saudi Arabia has allocated a budget to healthcare amounting to about USD 50.4 Billion to support improvements in the area of regenerative medicine. South Africa is regional frontrunner for the stem cell-based therapy initiatives developed and supported by the country's Department of Science and Innovation. The UAE is developing cell therapy research medical hubs through joint work with global institutions, the country's focus centers around sickle cell disease and diabetes treatments, issues within the region. By forming partnerships with international entities and acquiring government funding grants, the manufacturing capabilities to ensure these products are affordable, available, and accessible by increasing healthcare infrastructure, Africa and the Middle East are bound to be one of the rising contributors in the Cell Therapy market.

Competitive Landscape:

Major companies are bolstering the market with an array of offerings and methods. These pioneers in the field place a high priority on thorough research and development, constantly expanding the possibilities of cell therapies through the investigation of new cell types, delivery systems, and uses. They conduct rigorous clinical trials, substantiating the safety and efficacy of their therapies and obtaining regulatory approvals that enhance market credibility. They can take advantage of the combined expertise and resources of research institutions, biotech companies, and healthcare organizations through strategic alliances and collaborations. Leading businesses frequently broaden their market reach internationally, enabling a larger patient pool to access cell therapies. Maintaining strict compliance with regulatory standards ensures that their therapies meet stringent safety and quality requirements, instilling confidence among healthcare professionals and patients. Additionally, their crucial role in developing cell therapies and promoting market expansion is further reinforced by patient access improvement programs, educational campaigns, and strategic acquisitions.

The report has provided a comprehensive analysis of the competitive landscape in the cell therapy market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allogene Therapeutics
  • AlloSource
  • Bristol-Myers Squibb Company
  • Corestemchemon Inc
  • Gilead Sciences, Inc.
  • Holostem S.r.l
  • IOVANCE Biotherapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd
  • Legend Biotech
  • Mesoblast Ltd.
  • Sangamo Therapeutics
  • Tegoscience
  • Vericel Corporation

Key Questions Answered in This Report

  • 1.What is cell therapy?
  • 2.How big is the cell therapy market?
  • 3.What is the expected growth rate of the global cell therapy market during 2026-2034?
  • 4.What are the key factors driving the global cell therapy market?
  • 5.What is the leading segment of the global cell therapy market based on cell type?
  • 6.What is the leading segment of the global cell therapy market based on therapy type?
  • 7.What is the leading segment of the global cell therapy market based on therapeutic area?
  • 8.What are the key regions in the global cell therapy market?
  • 9.Who are the key players/companies in the global cell therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cell Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cell Type

  • 6.1 Stem Cell
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bone Marrow
      • 6.1.2.2 Blood
      • 6.1.2.3 Umbilical Cord-Derived
      • 6.1.2.4 Adipose-Derived Stem Cell
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-stem Cell
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapy Type

  • 7.1 Autologous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Allogeneic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapeutic Area

  • 8.1 Malignancies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Musculoskeletal Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dermatology
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Allogene Therapeutics
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AlloSource
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Corestemchemon Inc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Gilead Sciences, Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Holostem S.r.l
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 IOVANCE Biotherapeutics, Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 JCR Pharmaceuticals Co., Ltd
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Legend Biotech
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Mesoblast Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Sangamo Therapeutics
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Tegoscience
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Vericel Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cell Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cell Therapy Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cell Therapy Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Cell Therapy Market: Breakup by Cell Type (in %), 2025
  • Figure 5: Global: Cell Therapy Market: Breakup by Therapy Type (in %), 2025
  • Figure 6: Global: Cell Therapy Market: Breakup by Therapeutic Area (in %), 2025
  • Figure 7: Global: Cell Therapy Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Cell Therapy Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Cell Therapy (Stem Cell) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cell Therapy (Stem Cell) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cell Therapy (Non-stem Cell) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cell Therapy (Non-stem Cell) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cell Therapy (Autologous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cell Therapy (Autologous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cell Therapy (Allogeneic) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cell Therapy (Allogeneic) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cell Therapy (Malignancies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cell Therapy (Malignancies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cell Therapy (Musculoskeletal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cell Therapy (Musculoskeletal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cell Therapy (Autoimmune Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cell Therapy (Autoimmune Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cell Therapy (Dermatology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cell Therapy (Dermatology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cell Therapy (Other Therapeutic Areas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cell Therapy (Other Therapeutic Areas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cell Therapy (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cell Therapy (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cell Therapy (Academic and Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cell Therapy (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: North America: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Asia-Pacific: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Asia-Pacific: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: China: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: China: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Japan: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Japan: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: India: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: India: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: South Korea: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: South Korea: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Australia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Australia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Indonesia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Indonesia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Europe: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Europe: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Germany: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Germany: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: France: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: France: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: United Kingdom: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: United Kingdom: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Italy: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Italy: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Spain: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Spain: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Russia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Russia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Latin America: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Latin America: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Brazil: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Brazil: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Mexico: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Mexico: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Middle East and Africa: Cell Therapy Market: Breakup by Country (in %), 2025
  • Figure 79: Middle East and Africa: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Global: Cell Therapy Industry: SWOT Analysis
  • Figure 81: Global: Cell Therapy Industry: Value Chain Analysis
  • Figure 82: Global: Cell Therapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cell Therapy Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Cell Therapy Market Forecast: Breakup by Cell Type (in Million USD), 2026-2034
  • Table 3: Global: Cell Therapy Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
  • Table 4: Global: Cell Therapy Market Forecast: Breakup by Therapeutic Area (in Million USD), 2026-2034
  • Table 5: Global: Cell Therapy Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Cell Therapy Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cell Therapy Market: Competitive Structure
  • Table 8: Global: Cell Therapy Market: Key Players